Modus Therapeutics to present at Nordic Life Science Days 2015

Modus Therapeutics AB, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with sickle-cell disease, announces its Chief Executive Officer Christina Herder is to present at Nordic Life Science Days 2015 conference.

Modus Therapeutics’s lead candidate Sevuparin blocks key adhesion receptors involved in events leading up to a Vaso-Occlusive Crisis (VOC) in sickle cell disease patients, a disease poorly served by current treatment options as only symptomatic treatments currently are available.

Dr Christina Herder’s presentation at NLS Days will be entitled:

“Sevuparin in Sickle Cell Disease – Key to Major Shift in SCD?”

The presentation will take place at 12:15, September 10th 2015, at Stockholm Waterfront Congress Center, Sweden.

A Proof-of-Cconcept study for sevuparin in sickle cell disease will start enrolling patients later this year: The study will be a randomized, placebo-controlled double-blind study. The primary objective will be to assess time to resolution of painful VOC inhospitalized sickle cell disease patients.  At least 70 patients will be treated with intravenously administered sevuparin for 2-7 days, but the number of patients may be increased to 140 based on an interim analysis planned after 45 patients.

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. The event attracts leading decision makers from the Life Science sector from biotech, pharma and medtech; as well as finance, research, policy and regulatory authorities.